glp-1/gip/gcg receptor agonist Neurotrophic and neuroprotective effects of a monomeric triagonist in cellular and rodent models of mild traumatic brain injury Glucagon-like peptide-1 receptor co-agonists for

Obesity is a complex disease, excessive fat accumulation caused by genetic, environmental and other factors, that has seen the most rapid growth in terms of ...

Designed to complement your GLP-1 journey

Clinical Significance: The 2025 updates reaffirm that while HbA1c remains central, a one-number-fits-all strategy is outdated

Millions of Americans have turned to cheaper, compounded versions of Ozempic and Wegovy

This comprehensive review critically evaluates recent advances in BBRs anti-obesity pharmacology through three lenses: (1) preclinical and clinical evidence from randomized controlled trials, (2) molecular mechanisms underlying metabolic regulation, and (3) innovative strategies for pharmacokinetic optimization

Important conclusions drawn from recent meta-analyses involving over 300,000 patients report that while the retained gastric contents are significantly increased (fivefold to tenfold increase